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ABSTRACT
The endosialin/CD248/TEM1 receptor is expressed on the cell surface of tumor-
associated stroma cells as well as in sarcoma and neuroblastoma cells. This receptor 
is emerging as an attractive molecule in diagnostics and therapeutics because of its 
expression across the stroma of many human tumors, the low to absent expression 
in normal tissues and accessibility from the vascular circulation. In this study, we 
present evidence of the preclinical efficacy of a novel Antibody-Drug Conjugate 
(ENDOS/ADC). It consists of a humanized endosialin monoclonal antibody, named 
hMP-E-8.3, conjugated to a potent duocarmycin derivative. In endosialin expressing 
cancer cell lines, this ENDOS/ADC showed a powerful, specific and target-dependent 
killing activity. High expression levels of endosialin in cells correlated with efficient 
internalization and cytotoxic effects in vitro. Efficacy studies demonstrated that 
ENDOS/ADC treatment led to a long-lasting tumor growth inhibition of a cell line-
based model of human osteosarcoma. Taken together, our results demonstrate that 
endosialin is an attractive target in sarcoma and suggest that ENDOS/ADC has the 
potential to be developed into a bio-therapeutic agent for these malignancies.
INTRODUCTION
Endosialin (aka Tumor endothelial marker 1) is a cell 
surface protein encoded by the CD248 gene in humans, 
belonging to a family of C-type lectin transmembrane 
receptors. Endosialin expression is essentially restricted 
to activated cells of the mesenchymal lineage, including 
pericytes and myofibroblasts during embryogenesis [1–3]. 
Importantly, expression of endosialin is dramatically 
reduced in adults, but has been shown to be up-regulated 
during pathologic states, including tumor progression and 
metastasis [4, 5] making endosialin an oncofetal protein 
with potential as therapeutic target [6, 7].
Several reports have documented that endosialin 
is frequently expressed in human cancers. However, 
the extent and the intensity of expression varies among 
the different cancer subtypes, as well as individual cells 
composing the neoplastic mass [8]. In a large series of 514 
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human sarcomas including undifferentiated pleomorphic 
sarcomas, rhabdomyosarcoma, synovial sarcomas, adult 
fibrosarcoma/spindle cell sarcoma and leiomyosarcomas, 
more than half of the tumours displayed endosialin on 
neoplastic sarcoma cells, whereas, in the remaining cases 
endosialin expression was restricted to pericytes and 
stromal fibroblasts [9]. Likewise, in epithelial neoplasms of 
other lineages, including colorectal, breast, histiocytomas, 
highly invasive glioblastoma, anaplastic astrocytomas, 
and metastatic melanomas, expression of endosialin was 
confined to pericytes and stromal fibroblasts [8, 10, 11].
Sarcomas are a heterogeneous group of malignant 
tumors that share similar embryologic derivation 
(predominantly mesodermal), pathologic appearance, 
and clinical presentation and behavior. Many sarcomas 
behave aggressively, and surgery with or without radiation 
remains the mainstay of management for localized disease, 
as most are resistant to chemotherapy. As many sarcomas 
occur in sites where adequate surgical clearance is not 
possible, and the prognosis is generally poor for recurrent 
and metastatic disease, the need for novel rationally 
selected therapies is urgent.
Antibody-Drug Conjugates (ADCs) share the common 
feature of targeting internalizing cell surface proteins with 
an antibody covalently linked to a highly potent cytotoxic 
compound [12–14]. In principle, this enables higher local 
exposure of the tumor to the drug than that permissible by 
systemic delivery of the free drug. Recent advances in this 
technology have resulted in some very encouraging objective 
clinical responses, and numerous ADCs are now in various 
stages of development [15, 16]. In this study, we generated 
and characterized monoclonal antibodies against the extra-
cellular domain of human endosialin. One of the antibodies, 
hMP-E-8.3, was coupled via a peptidic linker to a potent 
duocarmycin derivative to generate an ADC. In endosialin 
expressing cancer cell lines, this novel ADC displayed specific 
and target-dependent killing activity and long-lasting tumor 
growth inhibition of cell line-based models of human sarcoma.
RESULTS
Fourteen murine monoclonal antibodies, recognizing 
the ECD of human endosialin were generated as described 
in the method section. Antibodies were screened for in vitro  
binding and cell binding by ELISA or fluorescence-
activated cell sorting (FACS) analysis. One murine antibody, 
mMP-E-8.3 was selected as lead compound displaying the 
highest affinity for the target protein (data not shown). The 
murine antibody was chimerized and after target binding 
validation, its CDRs were grafted into a human IgG1 isotype 
antibody framework (Supplementary Figure 1).
hMP-E-8.3 antibody binding and internalization
The antibody bound human endosialin with affinity 
in the nanomolar range (KD 0.94 to 5.0 nM), as determined 
using solid phase ELISA on human recombinant 
endosialin’s ECD and FACS analysis on live SJSA-1 
cells (Figure 1A). The antibody did not recognize murine 
endosialin; however it cross-reacted with cynomolgus’s 
placenta where endosialin membrane staining is observed 
on decidual cells (Supplementary Figure 2A-2B).
To evaluate the ability of hMP-E-8.3 to bind 
endosialin in vivo, SJSA-1 cells were grown as xenograft 
tumors in nude mice. After the tumors became about 400 
mm3 in volume, animals were injected with 250 μg of 
hMP-E-8.3. Twenty-four hours later, tumors were excised, 
snap frozen and sections stained with AlexaFluor-488 
conjugated anti-human IgG. A substantial uptake of the 
antibody was observed in tumor tissues of animals injected 
with hMP-E-8.3 but not with a control isotype matched 
IgG (Figure 1B).
To determine whether hMP-E-8.3 internalized upon 
binding to the cell surface, and therefore represented a 
candidate for cytotoxic payload conjugation, SJSA-1 
cells were exposed for 2 hrs to hMP-E-8.3 (10 μg /ml) 
or PBS and analyzed for endosialin expression by FACS. 
A marked (85%) reduction of surface expression of 
endosialin was observed in antibody treated cells (Figure 
1C left panel). Antibody internalization was confirmed by 
confocal imaging, showing a clear de-localization of the 
hMP-E-8.3 staining from the cell surface to the perinuclear 
intracellular compartment upon shifting the cells from ice 
to 37°C (Figure 1C, right panels). These results indicate 
that hMP-E-8.3 quickly and efficiently internalized in 
endosialin expressing cells.
Generation of ADC and in vitro cytotoxicity
A potent, soluble minor groove DNA binder (MGB) 
duocarmycin derivative bearing an enzymatic peptidic 
cleavable linker (valine-citrulline) was conjugated to 
monoclonal antibody hMP-E-8.3 by partial reducing the 
antibody and conjugating the drug to the available reduced 
inter-chain cysteine residues to produce ENDOS/ADC 
(Supplementary Figure 3A). The reaction conditions were 
optimized to produce a monomeric ADC with a DAR of 
3.5-4.0 (Supplementary Figure 3B-3C).
As first step, we compared the binding affinity 
of the ENDOS/ADC and naked hMP-E-8.3 antibody. 
SJSA-1 human osteosarcoma cells were chosen, as 
these cells expressed the highest levels of endosialin. 
FACS analysis performed on live SJSA-1 cells revealed 
no difference in binding between naked antibody and 
ENDOS/ADC (Figure 1D, left panel) indicating that 
the conjugation process did not alter the ability of the 
antibody to bind his target on cell surface. ENDOS/
ADC internalization ability in SJSA-1 cells was 
confirmed by confocal imaging. Of note, a marked 
accumulation of ENDOS/ADC occurred already 0.5 
hr after shifting cells from ice to 37°C (Figure 1 D, 
right panels).
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As a proof-of-concept of ENDOS/ADC activity 
in vitro, cell cycle analysis of ADC-treated SJSA-1 
cells was evaluated and compared to cells treated with 
PBS. Additionally, as a control of specificity, SJSA-1 
endosialin -/- cells were generated by CRISPR/CAS 9 
technology and assayed for cytotoxicity upon exposure 
to the ADC. The induced mutation in SJSA-1 endosialin 
-/- cells was validated by genomic DNA sequencing and 
the absence of expression of endosialin was confirmed 
by FACS analysis and western blotting (Figure 2A–2B). 
As expected, a complete S-G2 block was observed in 
wild-type cells after 48 hrs exposure to ENDOS/ADC; 
the block was completely absent in endosialin -/- cells 
(Figure 2C). These data clearly indicated that hMP-E-8.3 
antibody was able to deliver and release the conjugated 
payload into cancer cells in a target-dependent manner. 
Next, we tested the cytotoxic activity of ENDOS/ADC 
in four human tumor cell lines expressing different levels 
of endosialin: high (osteosarcoma SJSA-1), intermediate 
(neuroblastoma SKNAS and Ewing’s sarcoma A-673), 
or not expressing endosialin (metastatic A375 melanoma 
cells) (Figure 2D upper panel). SJSA-1 cells, which 
display the higher endosialin expression level, were the 
most sensitive to ENDOS/ADC with an IC50 = 0.8 nM; 
SKNAS and A-673 were also sensitive, with IC50 of 1.96 
and 8.6 nM, respectively, whereas A375 were resistant, as 
expected (IC50 > 100 nM) (Figure 2D lower panel).
These results indicate that the growth inhibitory 
activity of ENDOS/ADC correlates with the amount of 
target expression on the cell surface.
ADC efficacy and safety in an in vivo human 
osteosarcoma model
The therapeutic efficacy of ENDOS/ADC was 
evaluated in a human osteosarcoma SJSA-1 derived 
xenograft model. When tumors reached an average 
volume of around 100mm3, animals were divided in three 
arms and treated with a total of four injections (once every 
three days) with naked hMP-E-8.3 antibody (10 mg/kg), 
Figure 1: hMP-E-8. 3 binds endosialin in vitro/in vivo and is internalized into SJSA-1 cells. (A) Binding of hMP-E-8.3 to human 
recombinant endosialin’s ECD by ELISA (left) or FACS analysis on living osteosarcoma SJSA-1 cells (right). (B) Binding of hMP-E-8.3 
to endosialin in vivo as evaluated by immunofluorescence analysis of SJSA-1 tumor xenografts. Animals received a single injection of 
human IgG (as a control), or hMP-E-8.3, both at the dose of 10 mg/Kg. Twenty-four later, animals were sacrificed, the tumors frozen 
and tumor sections stained with AlexaFluor-488 conjugated anti-human IgG (green), a commercial antibody against human endosialin 
followed by AlexaFluor-546 conjugated anti-rabbit antibody staining (red) or Draq5 (blue). (C) Flow cytometry analysis (left panel) 
of endosialin surface expression in SJSA-1 cells cultured in the presence of hMP-E-8.3 (10 μg/ml) at 37°C for 2 hrs. The antibody is 
efficiently internalized as revealed by a marked reduction of endosialin expression (85% in 2 hrs). Fluorescence immunocytochemistry 
(right panels) of hMP-E-8.3 internalization in SJSA-1 cells. Cells were incubated with hMP-E-8.3 on ice for 20 min, then shifted at 37°C 
for 2 hrs. After harvesting, cells were stained with AlexaFluor-488 conjugated anti-human IgG (green). Draq5 (blue) was used to visualize 
nuclei. Yellow arrows indicate intracellular staining. Images were acquired with LSM-510 laser scanning confocal microscopy. (D) Flow 
cytometry analysis (left panel) of endosialin surface expression in SJSA-1 cells as evaluated by naked hMP-E-8.3 antibody or ENDOS/
ADC. Confocal imaging (right panels) of ENDOS/ADC internalization in SJSA-1 cells. Cells were incubated with ENDOS/ADC (10 μg/
ml) on ice for 20 min, then shifted at 37°C for the indicated times. After harvesting, cells were stained with AlexaFluor-488 conjugated 
anti-human IgG (green), Rhodamine-labeled phalloidin was used to visualize actin cytoskeleton (red), Draq 5 (blue) for nuclei staining.
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ENDOS/ADC (10 mg/kg), or PBS (as a control group). 
The naked antibody slightly reduced tumor growth, 
although reduction was not statistically significant, whilst 
a significant tumor remission was observed in mice 
treated with ENDOS/ADC (Figure 3A). No differences 
in terms of body weight loss or tumor tissues cellular 
architecture was observed in any of the treatment groups 
(Figure 3B and Supplementary Figure 3D). A reduced 
treatment schedule, i.e a total of two injections a week 
apart was similarly effective in producing a complete 
tumor remission (Figure 3C). Of note, at day 11th two out 
of five mice showed a complete remission, resulting in 
a prolonged survival of 100+ days after the start of the 
treatment. (Log-rank test p= 0.02, Figure 3D-3E). On the 
contrary, no tumor response was observed in endosialin -/- 
derived xenografts (Figure 3F). The lack of expression of 
endosialin in xenografts derived from endosialin -/- cells 
and the accumulation of ENDOS/ADC in wild-type cells 
were confirmed by immunohistochemistry (IHC) (Figure 
3G–3H). These results show that the therapeutic activity 
of ENDOS/ADC is specific and dependent on the target.
DISCUSSION
Osteosarcomas and more in general sarcomas are 
malignant tumors that most commonly affect children, 
adolescents, and young adults. Despite advances in the 
treatment with the introduction of new surgical techniques 
and innovative drugs, these tumors can be hard to treat and 
novel therapies are urgently needed.
ADCs are an emerging new class of targeted 
therapeutics that are particularly attractive because they 
combine the selectivity of antibodies toward the target with 
the potent cell killing activity of cytotoxic drugs [13, 17]. 
ADCs can deliver these drugs in the picomolar range 
directly inside the tumor cells. To date, there are two FDA 
approved ADCs and more than thirty in clinical trials [14]. 
In order to ensure the required specificity, it is necessary that 
the armed antibody is directed to a target which is abundant 
on the surface of cancer cells, but not normal cells.
Endosialin is a cell surface receptor detected in 
mesenchymal tumors, such as sarcoma, neuroblastoma 
other than in perivascular and tumor-associated stroma. The 
exact role of endosialin is still largely unknown. However, 
Figure 2: ENDOS/ADC in vitro cytotoxic activity correlates with endosialin expression.  Endosialin -/- SJSA-1 cells were 
generated by CRISPR-Cas9 system of genome editing. Lack of endosialin expression was documented by (A) FACS analysis and (B) Western 
blotting. (C) Cell cycle analysis was performed after exposure of wild-type or endosialin -/- SJSA-1 cells to 0.4 μg/ml of ENDOS/ADC. (D) 
Levels of endosialin surface expression determined by cytometry analysis using hMP-E-8.3 antibody for cells staining (upper panel). ENDOS/
ADC cell killing activity (lower panel) after 120hrs of cells exposure to increasing doses of ENDOS/ADC. The following human cancer cell 
lines and tissue of origin were used: SJSA-1, osteosarcoma; SKNAS, neuroblastoma; A673 Ewing’s sarcoma; A375 melanoma. The values are 
expressed as mean ± SD of three experiments. IC50 and best-fit curve were calculated using GraphPad Prism 5 software.
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its implication in tumour neoangiogenesis and the observed 
high expression levels in malignant cells has stimulated 
the development of therapeutics targeting this receptor. 
Importantly, normal adult tissues do not express endosialin, 
making it an ideal target for an ADC based therapy.
In this study, we have generated an ADC targeting 
endosialin based on a novel humanized anti-endosialin 
antibody, hMP-E-8.3. Compared to the naked antibody, 
ENDOS/ADC displayed similar binding affinity for 
the target. The novel ADC was endowed with a marked 
and durable antitumor activity which is dependent on 
target expression. Other antibodies targeting endosialin 
have been developed, mainly with the aim of targeting 
endosialin expression in the vasculature and stromal cells 
of carcinomas [18–21]. Recently, an anti-endosialin/
Monomethyl Auristatin E (MMAE) conjugate has 
been generated and found to be effective in targeting 
neuroblastoma and Ewing sarcoma in preclinical in vitro 
and in vivo models [22]. In our study, ENDOS/ADC 
treatment produced a significant tumor response with only 
two injections, one week apart, in a model of osteosarcoma 
(SJSA-1). Besides the different tumor models used, the 
key distinction between these two reports lies in the 
different nature of the payload, a DNA alkylating agent 
versus a microtubule disruptor.
The present proof-of-concept study demonstrates 
that endosialin positive osteosarcomas can be specifically 
and effectively targeted by the anti-endosialin antibody 
hMP-E-8.3 conjugated to a potent MGB duocarmycin 
derivative. The therapeutic efficacy demonstrated by this 
ADC deserves further preclinical testing in endosialin 
positive malignancies other than osteosarcomas.
Figure 3: Therapeutic activity of ENDOS/ADC against SJSA-1 osteosarcoma xenografts. (A) Mice were implanted 
subcutaneously with 2x106 SJSA-1 cells. When tumors reached a volume of ~100 mm3, mice were randomly grouped (N=5) and 
intravenously injected every 3 days with vehicle (PBS), naked hMP-E-8.3 antibody (10 mg/kg), or ENDOS/ADC (10 mg/kg) for a total of 
4 injections. (B) No significant treatment-related body weight loss was registered. (C) Growth curves of SJSA-1 tumor xenografts treated 
with a reduced schedule (two injections of 10 mg/kg ENDOS/ADC one week a part). (D) Plot of single animals tumor volumes at day 
11th. (E) Survival curve evaluated by Kaplan-Meier and analyzed by the log-rank test. (F) Growth curves of endosialin -/- SJSA-1 derived 
xenografts treated as in C. IHC staining of endosialin (G) or ENDOS/ADC (H) in wild-type or endosialin -/- SJSA-1 derived xenografts. 




As positive control for mouse cross reactivity assays 
was used the commercial rabbit anti-endosialin antibody 
18160-1-AP from Proteintech (Proteintech Group Inc., 
Chicago, IL, USA) which has been reported to bind 
murine endosialin [23].
Actin antibody from Sigma-Aldrich (St Louis, 
MO, USA). 3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) was purchased from Sigma 
(Sigma Aldrich Corporation, St. Louis, MO, USA). 
Recombinant human endosialin (CD248) was purchased 
from R&D (R&D Systems, Inc., Minneapolis, MN, USA).
Cell lines
Sarcoma (SJSA-1), melanoma (A375m), neuroblastoma 
(SKNAS) and Ewing sarcoma (A673) cells were purchased 
from American Type Culture Collection (Rockville, MD, 
USA). The cells were cultured according to manufacturer’s 
instructions, in a medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Invitrogen), l-glutamine, 
100 units/ml penicillin, and 100 μg/ml streptomycin (Sigma-
Aldrich Corporation, St. Louis, MO, USA), and incubated at 
37 °C in humidified air with 5% CO2.
Generation and characterization of anti-
endosialin antibodies
Four-weeks old Balb/c mice were immunized 
by intraperitoneal injection as emulsions in Complete 
Freund’s Adjuvant (CFA) or Incomplete Freund’s Adjuvant 
(IFA). Seven days later, mice were given an additional 
intraperitoneal injection of the immunogen consisting of a 
mixture of peptides with specificity for the extra-cellular 
domain of endosialin, as reported in Supplemental Figure 
1 (sequence of peptide of mMP-E-8.3 highlighted). After 
additional seven days, mice were boosted intravenously 
with the immunogen, and spleens were removed for cell 
fusion 3 days later. Somatic cell hybrids were prepared by 
fusion of immune splenocytes with the murine nonsecreting 
myeloma cell line NS-1 by standard procedures [24]. 
Hybridoma cell lines expressing antibodies recognizing 
the ECD of human recombinant endosialin in ELISA were 
subcloned four to six times to ensure that the cell line was 
monoclonal and stable. Monoclonal hybridoma cell lines 
were grown in RPMI 1640 medium supplemented with 
5% fetal calf serum (Invitrogen, Carlsbad, CA, USA) for 
2–3 weeks. IgG were purified over protein G-Sepharose 4 
Fast Flow (Amersham Biosciences, Little Chalfont, UK) 
according to standard procedures [25].
Binding and affinity of the antibodies was 
determined by solid phase ELISA using immobilized 
human ECD recombinant and FACS analysis using 
live SJSA-1 human osteosarcoma cells, respectively. 
The concentration of antibody required for obtain 50% 
of maximal binding was considered the Kd value. The 
antibody displaying the highest affinity was selected as 
lead compound and named mMP-E-8.3.
Antibody humanization
The mMP-E-8.3 antibody was humanized by CDRs 
grafting into an IgG1 scaffold as previously described [26]. 
Briefly, in a first step a chimeric variant of the mMP-E-8.3 
antibody was generated by fusing the VH (variable domain 
of the heavy chain) and VL (variable domain of the light 
chain) of the murine antibody to the corresponding 
human constant domains. Successively, humanized MP-
E-8.3 variants were generated by identifying murine 
complementary determinant regions (CDR) which were 
grafted onto a human antibody framework. Recombinant 
genes were placed into the pCDNA3.1 expression vector 
and transfected into Chinese Hamster Ovary-S (CHO) 
cells. Antibody variants were screened for antigen binding 
affinity by ELISA and FACS and lead candidate was 
selected and named hMP-E-8.3.
For small/medium scale production of antibody 
variants, transiently transfected CHO cells were grown 
using a benchtop BioFlo 3000 bioreactor (New Brunswick 
Scientific); antibody-containing supernatants were purified 
by ultrafiltration (VivaFlow-200 membrane Sartorium 
stedim Biotech) and immune selection on a Protein-A 
(Pall Protein A ceramic HyperD F) affinity matrix. The 
selected hMP-E-8.3 antibody is a G1m17 IgG1 allotype 
with a human km3 kappa LC.
ELISA
Human recombinant endosialin (1 μg/ml) was 
pre-coated overnight at 4°C on 96 well-plates NUNC 
Maxisorp modules. After blocking with 1% BSA in 
PBS containing 0,05 % Tween-20 for 1 hour at room 
temperature, mMP-E-8.3 or hMP-E-8.3 was added and 
incubated at the indicated concentration for 2 hours at 
room temperature. After several washes with PBS-0,05 
% Tween-20, anti-mouse IgG-HRP or anti-human IgG-
HRP (from Bio-Rad; Hercules, California, USA) were 
added and incubated for 1 hour at room temperature. After 
washes, stabilized chromogen was added for at least 10 
minutes in the dark, before stopping the reaction with the 
addition of 1 N H2SO4. The resulting color was read at 450 
nm with an Elisa reader.
FACS analysis
Endosialin cell surface expression was analyzed by 
flow cytometry using a FACSCalibur cytometer (Becton 
Dickinson, Buccinasco, MI, Italy). Briefly, around one 
million of proliferating cells were harvested and labeled 
with hMP-E-8.3 on ice for 20 minutes. Cells were then 
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washed with 2 ml PBS, pulled down, and stained with an 
Alexa Fluor 488 Goat anti-Human antibody (Molecular 
Probes, Life Technologies, Paisley, UK). The data were 
analyzed using CELLQuest 3.2.1.f1 software (Becton 
Dickinson).
Cell Cycle was analyzed by flow cytometric 
evaluation of DNA content according to the Nicoletti 
method [27]. 2×106 cells were harvested by centrifugation 
at 800g for 5 min and fixed in 70% ethanol at 4ºC 
overnight. Cells were then washed twice with PBS and 
stained in 0.5 ml PBS containing Propidium iodide (PI, 
50 μg/ml) and RNAase (10 μg/ml) 4°C overnight in the 
dark. 20,000 singlet gated events were acquired using a 
FACSCanto II cytometer (Becton Dickinson, Buccinasco, 
MI, Italy). Finally, data were analyzed using FLOW JO, 
LLC software.
ADC preparation
A potent, soluble Minor Groove DNA Binder 
(MGB) duocarmycin derivative bearing an enzymatic 
peptidic cleavable linker (valine-citrulline) was conjugated 
to hMP-E-8.3 by partial reducing the antibody and 
conjugating the drug to the available reduced interchain 
cysteine residues.
The product was characterized by SDS-PAGE under 
reducing and not reducing conditions, size exclusion 
chromatography (SEC) to determine the aggregate 
state, hydrophobic interaction chromatography (HIC) to 
evaluate the presence of different loaded isoforms in native 
conditions, and PRLP LC/MS in reducing conditions to 
determine the Drug to Antibody Ratio (DAR). The sample 
was totally reduced to separate Light and Heavy chains 
before submitting to LC/MS analysis. The MW of the 
single species was determined by mass spectrometry on a 
single quadrupole instrument Agilent 1946. The presence 
of the drug was confirmed by absorbance at 320 nm in the 
chromatographic peaks and DAR calculated by the ratio 
between 320nm/280nm absorbancies.
Endosialin gene disruption by CRISPR-Cas9 
system
Endosialin expression was ablated in SJSA-1 cells 
by means of CRISPR-Cas9 system of genome editing in 
accordance with the protocol developed by Zhang and co-
workers [28, 29].
Target selection for sgRNA.
A 20 nucleotide sgRNA (single guide RNA) target 
sequence (AAGGGCGTGGTATACACGGC), immediately 
followed by a PAM sequence (TGG) for S. piogenes Cas-9, 
was identified into the antisense strand of endosialin locus, 
through the CRISPR design tool (crispr.mit.edu).
Generation of single guide expression plasmid
Endosialin CRISPR plasmid was generated by 
cloning annealed oligos for target sequence into the BbsI 
restriction site of pX330 (Addgene 42230), bearing both 
sgRNA scaffold and S. piogenes Cas-9 endonuclease.
Cells transfection and isolation of clonal cell lines by 
FACS
Endosialin CRISPR was transiently co-tranfected 
with a GFP expression plasmid in SJSA-1 cells using 
the Calcium Phosphate transfection Kit, (ThermoFisher 
Scientific; Waltham, Massachussets, USA). 48 hrs after 
transfection, single GFP-positive cells were isolated by 
cell sorting (FACS ARIA III, BD Biosciences, San Jose, 
CA) and seeded into 96 well plates.
Identification of endosialin KO cell line
Colonies arising from a single cell were replica 
plated and genomic DNA was harvested using 
QuickExtract (EpiCentre). The target region was PCR 
amplified (Fw primer: 5’-tacctgtgccagtttggcttc-3’; Rev 
5’- tgcttcacgcagagcagagag -3’) and amplification bands 
were cloned using the TOPO® TA kit [Invitrogen], Sanger 
sequenced (Eurofins genomics) and aligned to observe the 
individual mutations and identify KO clones. Sequencing 
shows two base-pair deletion in one allele and twenty-five 
base-pair deletion in the other, both resulting in a frame-
shift. All oligonucleotides were synthesized by Integrated 
DNA Technologies (IDT).
Internalization assays
SJSA-1 cells were plated in 12 well-plates and grown 
in 10% FBS RPMI-1640 for 24 hours. Cells were then 
incubated with 10 μg/ml of hMP-E-8.3 for 30 minutes on 
ice and returned at 37°C for 2 hours. After 2 hours, cells 
were stained with a goat anti-human Alexa 488-conjugated 
secondary antibody (ThermoFisher Scientific; Waltham, 
Massachussets, USA) and samples were analyzed by 
flow cytometry using a FACSCalibur cytometer (Becton 
Dickinson, Buccinasco, MI, Italy). Finally, data were 
analyzed using CELLQuest 3.2.1.f1 software (Becton 
Dickinson). For confocal imaging, after 0.5 or 2 hours, 
cells were fixed in 4% paraformaldehyde for 15 minutes at 
room temperature, permeabilized with 0.25% Triton-X100 
in PBS for 5 minutes, and blocked with 5% goat serum 
in PBS for 30 minutes at room temperature. Then cells 
were stained for 1 hour at room temperature with a goat 
anti-human Alexa 488-conjugated secondary antibody 
(Molecular Probes, Life Technologies, Paisley, UK) (green 
staining) and with Rhodamine-labelled phalloidin (Sigma-
Aldrich Corporation, St. Louis, MO, USA). Cell nuclei 
were counterstained in blue using DRAQ5 (Cell Signaling 
Technology, Danvers, MA, USA). Images were acquired 
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with a Zeiss LSM 510 meta-confocal microscope (Zeiss, 
Oberkochen,Germany) using 488-, 543-, and 633-nm lasers.
Cell viability assay
Cells were seeded at a density of 7 x 104 cells/
well in 24-well plates in 10% FBS containing medium 
and allowed to attach and propagate overnight before 
the treatments. The cells were washed once with pre-
warmed phosphate-buffered saline (PBS) and exposed 
to the specified experimental conditions as indicated. 
After treatment, cells were incubated with MTT (final 
concentration of 0.5 mg/ml) at 37 °C for 2 hours. 
Spectrophotometric absorbance of the samples was 
determined at 570 nm. All experiments were performed 
in quadruplicate.
In vivo tumor growth
Athymic CD-1 nu/nu mice (5-7 weeks old) were 
purchased from Charles River Laboratories (Calco, 
LC, Italy) and maintained under specific pathogen-free 
conditions with food and water provided ad libitum and 
the animals’ health status was monitored daily. Procedures 
involving animal and their care were established according 
to the institutional guidelines in compliance with national 
and international policies (Authorization n° 973/2016-PR).
For in vivo ADC testing, human osteosarcoma 
cancer xenografts were established by implanting 
subcutaneously 2x106 SJSA-1 cells in 5-week old CD1 
female nude mice. When xenografts became palpable 
(with a tumor volume average of about 100 mm3), mice 
were divided in a manner to provide a similar range of 
tumor size in each group. Tumor volumes were monitored 
by a caliper every week and volumes calculated according 
to the following formula: tumor volume = (length 
* width2)/2. Mean volumes of treated and untreated 
xenografts were compared using an unpaired t test 
(Student’s t test) considering as statistically significant a 
P value < 0.05 (CI 95%). A tumor volume of 2 cm3 was 
chosen as endpoint for both experiments after which 
mice were sacrificed. Survival curves were derived from 
Kaplan-Meier estimates and compared by log-rank test 
(GraphPad Prism 5).
Immunohistochemistry
For endosialin staining of murine stomach and 
tumor tissues from xenografts experiments, tissues were 
fixed in 4% buffered formalin for 24 hours at room 
temperature. The fixed tissues were then dehydrated 
in ethanol, cleared in bioclear and then embedded in 
paraffin. Sections were cut to a thickness of 3 μm and 
taken on positively charged slides. Tissue sections 
were rehydrated in a graded alcohol series and rinsed 
in running tap water. Epitope retrieval was achieved by 
boiling the tissue sections in sodium citrate buffer (0.01 
M, pH 6), in a microwave owen for 10 minutes. Slides 
were rinsed in distilled water and then in Tris-buffered 
saline (0.05 M, pH 7.6).
Slides were preincubated with 1% bovine serum 
albumin in Phosphate Buffer Solution (BSA/PBS) for 
30 min at room temperature and then incubated with 
hMP-E-8.3 (5 μg/ml) overnight at 4 °C. As a positive 
control, slides were incubated with a rabbit monoclonal 
antibody recognizing murine endosialin (Proteintech, 
1:100 dilution). After washing, goat anti-human and goat 
anti rabbit, both HRP-conjugated were applied for 1 h at 
room temperature. Finally, slides were incubated with 
diaminobenzidine (DAB, DAKO) and coverslipped with 
an antifade-containing mounting medium (DAKO). To 
evaluate hMP-E-8.3 cross reactivity with monkey, a frozen 
tissue micro array (TMA) from US Biomax (# FCY 301a) 
was used and processed according to the manufacturer’s 
protocol.
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